Gilead Sciences Inc. — Sponsor Intelligence | 42 EU Trials

Filter these 42 trials by condition, phase, country and more.

Open in Search →

42 Registered trials

13 Recruiting

28 Completed trials

19 Countries active

68 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I (Other)

Phase III: 16 Phase II/III: 6 Phase II: 10 Phase IV: 3 Phase I: 2 Phase I (Other): 4 Phase I (FiH): 1

Oversight events:

1 serious breach 14 temporary halts 2 urgent safety measures 4 unexpected events 1 corrective measure across 8 trials

View oversight register →

100%

28 of 28 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 2 Neoplasm malignant 1 Triple negative breast cancer 1 Chronic hepatitis 1 Endometrial cancer recurrent 1 Neoplasm 1 Small cell lung cancer extensive stage 1 Cutaneous lupus erythematosus 1 Rheumatoid arthritis 1 COVID-19 1 Hormone receptor positive breast cancer 1 Chronic hepatitis B 1

Top IMPs

SACITUZUMAB GOVITECAN 12 CARBOPLATIN 6 PACLITAXEL 6 EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR 5 PACLITAXEL ALBUMIN-BOUND 5 PEMBROLIZUMAB 5 DOMVANALIMAB 4 LENACAPAVIR 4 ZIMBERELIMAB 4 BICTEGRAVIR, LENACAPAVIR 3 CISPLATIN 3 DOCETAXEL 3

All trials — page 2

42 total

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended

2023-504195-14-00 Phase III 12 countries CARBOPLATIN; GEMCITABINE; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; SACITUZUMAB GOVI…
A Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Ended

2024-513611-28-00 Phase II 3 countries SACITUZUMAB GOVITECAN
A Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non−Small-Cell Lung Ca… Ended

2024-513225-23-00 Phase II 4 countries CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
A study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Ended

2024-512148-50-00 Phase III 10 countries DOCETAXEL; SACITUZUMAB GOVITECAN
A study to evaluate the safety and tolerability of seladelpar in subjects with primary biliary cholangitis Ended

2024-511753-22-00 Phase III 12 countries SELADELPAR
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Expos… Ended

2022-501763-40-00 Phase III 7 countries EMTRICITABINE, TENOFOVIR ALAFENAMIDE
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection Halted

2023-506143-42-00 Phase II 1 country TENOFOVIR ALAFENAMIDE
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended

2024-512505-66-00 Phase II/III 5 countries EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR; GS-1720; GS-4182
N/A Ended

2024-513121-22-00 Phase II 3 countries CARBOPLATIN; DOMVANALIMAB; PACLITAXEL; ZIMBERELIMAB
Study in Participants With Normal Kidney Function and Reduced Kidney Function to Test How Kidney Function Can Change What Happens to Obeldes… Ended

2023-504780-17-00 Phase I (Other) 1 country GS-5245
Study of B/F/TAF in Participants Switching from CAB + RPV to B/F/TAF for HIV-1 Infection. Ended

2023-506660-13-00 Phase IV 1 country EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR
Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE) Ended

2022-501523-24-00 Phase II 3 countries GS-5718-03
Study of GS-4528 for Adults With Solid Tumors Ended

2022-502070-16-00 Phase I 1 country
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended

2022-500177-13-00 Phase II 5 countries BEVACIZUMAB; CALCIUM LEVOFOLINATE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROC…
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local… Ended

2024-513870-23-00 Phase III 8 countries DOCETAXEL; PACLITAXEL; SACITUZUMAB GOVITECAN; VINFLUNINE
Study of Sacituzumab Govitecan’s Long-Term Safety in Subjects with Metastatic Solid Tumors Ended

2023-505336-34-00 Phase IV 3 countries SACITUZUMAB GOVITECAN
N/A Ended

2024-517526-26-00 Phase III 1 country TENOFOVIR DISOPROXIL
Study of Obeldesivir in Children and Adolescents With COVID-19 Ended

2023-503282-27-00 Phase II/III 5 countries GS-5245

Showing 25–42 of 42 trials

← All sponsors A–Z